BR9809055A - Compostos de 4-amino-pirido(2,3-d)pirimidina 5,7-dissubstituìda e seu uso como inibidores de adenosinocinase - Google Patents
Compostos de 4-amino-pirido(2,3-d)pirimidina 5,7-dissubstituìda e seu uso como inibidores de adenosinocinaseInfo
- Publication number
- BR9809055A BR9809055A BR9809055-0A BR9809055A BR9809055A BR 9809055 A BR9809055 A BR 9809055A BR 9809055 A BR9809055 A BR 9809055A BR 9809055 A BR9809055 A BR 9809055A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- heterocyclic
- compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- -1 5,7-disubstituted 4-amino-pyrido (2,3-d) pyrimidine compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"COMPOSTOS DE 4-AMINO--PIRIDO[2,3-d]PIRIMIDINA 5,7-DISSUBSTITUìDA E SEU USO COMO INIBIDORES DE ADENOSINOCINASE" Método para inibir adenosinocinase administrando um composto que tem a fórmula (I) onde R^ 1^ e R^ 2^ são independentemente selecionados entre H, alquila inferior, alcóxi (C~ 1~-C~ 6~)-alquila (C~ 1~-C~ 6~), aril-alquila (C~ 1~-C~ 6~), -C(O)-alquila (C~ 1~-C~ 6~), -C(O)-arila, -C(O)-heterocíclico, ou podem unir-se ao nitrogênio ao qual eles estão anexados, para formar um anel de 5 a 7 membros, contendo opcionalmente 1 a 2 heteroátomos adicionais, selecionados entre O, N ou S; R^ 3^ é selecionado em grupo consistindo de alquila inferior, alquenila inferior, alquinila inferior, ciclo-alquila, arila, aril-alquila, heteroarila, grupo heterocíclico, heteroaril-alquila ou heterociclo-alquila, em que os grupos heteroarila e heterocíclico estão ligados diretamente ou indiretamente por um carbono anelar; R^ 4^ é selecionado em grupo consistindo de alquila inferior, alquenila inferior, alquinila inferior, ciclo-alquila, arila, aril-alquila, heteroarila, grupo heterocíclico, heteroaril-alquila ou heterociclo-alquila; e uma linha tracejada - - - indica que uma dupla ligação está opcionalmente presente, desde que as valências apropriadas sejam mantidas, uma composição farmacêutica que compreende uma quantidade terapeuticamente eficaz de um desses compostos acima em combinação com um excipiente de uso farmacêutico, e um método para tratar isquemia cerebral, epilepsia, nicipercepção, inflamação e sepse em um mamífero que necessite desse tratamento, que compreende administrar ao mamífero uma quantidade terapeuticamente eficaz de um composto desses, um processo para preparar esses compostos, e compostos que têm a fórmula acima na qual R^ 1^, R^ 2^, R^ 3^ e R^ 4^ são definidos separadamente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83821697A | 1997-04-16 | 1997-04-16 | |
| PCT/US1998/007207 WO1998046605A1 (en) | 1997-04-16 | 1998-04-14 | 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their use as adenosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9809055A true BR9809055A (pt) | 2000-08-08 |
Family
ID=25276561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9809055-0A BR9809055A (pt) | 1997-04-16 | 1998-04-14 | Compostos de 4-amino-pirido(2,3-d)pirimidina 5,7-dissubstituìda e seu uso como inibidores de adenosinocinase |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0989986A1 (pt) |
| JP (1) | JP2001520655A (pt) |
| KR (1) | KR20010006509A (pt) |
| CN (1) | CN1252070A (pt) |
| AR (1) | AR012436A1 (pt) |
| AU (1) | AU7108398A (pt) |
| BG (1) | BG103842A (pt) |
| BR (1) | BR9809055A (pt) |
| CA (1) | CA2286909A1 (pt) |
| CO (1) | CO4940446A1 (pt) |
| HU (1) | HUP0001434A3 (pt) |
| IL (1) | IL131618A0 (pt) |
| NO (1) | NO995036L (pt) |
| PL (1) | PL336304A1 (pt) |
| SK (1) | SK141799A3 (pt) |
| TR (1) | TR199902455T2 (pt) |
| WO (1) | WO1998046605A1 (pt) |
| ZA (1) | ZA983177B (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000023444A1 (en) * | 1998-10-21 | 2000-04-27 | Abbott Laboratories | 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds |
| DE60206363T2 (de) | 2001-02-12 | 2006-07-06 | F. Hoffmann-La Roche Ag | 6-substituierte pyridopyrimidine |
| JP2005526714A (ja) | 2002-01-17 | 2005-09-08 | ニューロジェン・コーポレーション | カプサイシンのモジュレーターとしての置換キナゾリン−４−イルアミン類縁体 |
| DE10335183A1 (de) * | 2003-07-30 | 2005-02-24 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
| CA2614443C (en) * | 2005-07-21 | 2011-03-22 | F. Hoffmann-La Roche Ag | Pyrido [2,3-d] pyrimidine-2,4-diamine compounds as ptp1b inhibitors |
| CA2633757A1 (en) * | 2005-12-21 | 2007-07-05 | Abbott Laboratories | Anti-viral compounds |
| EP1971611B1 (en) | 2005-12-21 | 2012-10-10 | Abbott Laboratories | Anti-viral compounds |
| US8236950B2 (en) | 2006-12-20 | 2012-08-07 | Abbott Laboratories | Anti-viral compounds |
| WO2009029632A1 (en) * | 2007-08-27 | 2009-03-05 | Helicon Therapeutics, Inc. | Therapeutic isoxazole compounds |
| WO2009028588A1 (ja) | 2007-08-31 | 2009-03-05 | Eisai R & D Management Co., Ltd. | 多環式化合物 |
| DE102007061764A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Anellierte Cyanopyridine und ihre Verwendung |
| CN102333777B (zh) * | 2009-02-26 | 2014-06-25 | 卫材R&D管理有限公司 | 含氮的稠合杂环化合物及其作为β淀粉样蛋白生成抑制剂的用途 |
| US9550750B2 (en) | 2012-10-05 | 2017-01-24 | Merck Sharp & Dohme Corp. | Indoline compounds as aldosterone synthase inhibitors |
| DK3436434T3 (da) | 2016-03-31 | 2020-09-21 | Oncternal Therapeutics Inc | Indolin-analoger og anvendelser deraf |
| CN110256420B (zh) * | 2019-05-07 | 2020-04-28 | 江西中医药大学 | 四氢吡啶并嘧啶衍生物及其制备方法和用途 |
| CN110283171A (zh) * | 2019-07-17 | 2019-09-27 | 鼎泰(南京)临床医学研究有限公司 | 一类含有吡啶并嘧啶-4-胺类结构的化合物、药物组合物以及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5324731A (en) * | 1989-02-14 | 1994-06-28 | Amira, Inc. | Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated |
| IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US6143749A (en) * | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
-
1998
- 1998-04-14 TR TR1999/02455T patent/TR199902455T2/xx unknown
- 1998-04-14 SK SK1417-99A patent/SK141799A3/sk unknown
- 1998-04-14 CN CN98804151A patent/CN1252070A/zh active Pending
- 1998-04-14 EP EP98918093A patent/EP0989986A1/en not_active Withdrawn
- 1998-04-14 BR BR9809055-0A patent/BR9809055A/pt not_active Application Discontinuation
- 1998-04-14 PL PL98336304A patent/PL336304A1/xx unknown
- 1998-04-14 IL IL13161898A patent/IL131618A0/xx unknown
- 1998-04-14 AU AU71083/98A patent/AU7108398A/en not_active Abandoned
- 1998-04-14 KR KR1019997009599A patent/KR20010006509A/ko not_active Withdrawn
- 1998-04-14 CA CA002286909A patent/CA2286909A1/en not_active Abandoned
- 1998-04-14 HU HU0001434A patent/HUP0001434A3/hu unknown
- 1998-04-14 WO PCT/US1998/007207 patent/WO1998046605A1/en not_active Ceased
- 1998-04-14 JP JP54408898A patent/JP2001520655A/ja active Pending
- 1998-04-15 ZA ZA983177A patent/ZA983177B/xx unknown
- 1998-04-15 AR ARP980101733A patent/AR012436A1/es unknown
- 1998-04-16 CO CO98020979A patent/CO4940446A1/es unknown
-
1999
- 1999-10-15 NO NO995036A patent/NO995036L/no not_active Application Discontinuation
- 1999-10-29 BG BG103842A patent/BG103842A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO995036D0 (no) | 1999-10-15 |
| HUP0001434A3 (en) | 2001-01-29 |
| NO995036L (no) | 1999-10-15 |
| AR012436A1 (es) | 2000-10-18 |
| CN1252070A (zh) | 2000-05-03 |
| IL131618A0 (en) | 2001-01-28 |
| TR199902455T2 (xx) | 2000-01-21 |
| CA2286909A1 (en) | 1998-10-22 |
| AU7108398A (en) | 1998-11-11 |
| HUP0001434A2 (hu) | 2000-10-28 |
| EP0989986A1 (en) | 2000-04-05 |
| PL336304A1 (en) | 2000-06-19 |
| KR20010006509A (ko) | 2001-01-26 |
| BG103842A (bg) | 2000-06-30 |
| SK141799A3 (en) | 2000-08-14 |
| CO4940446A1 (es) | 2000-07-24 |
| ZA983177B (en) | 1999-01-22 |
| JP2001520655A (ja) | 2001-10-30 |
| WO1998046605A1 (en) | 1998-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9809055A (pt) | Compostos de 4-amino-pirido(2,3-d)pirimidina 5,7-dissubstituìda e seu uso como inibidores de adenosinocinase | |
| UY25993A1 (es) | Procedimiento para preparar derivados del acido hidroxi-pipecolato hidroxamico | |
| BR0109109A (pt) | Composto, uso do mesmo, processo para prepará-lo, composição farmacêutica, e, método de tratar um estado doentio mediado por ccr5 em mamìferos | |
| BRPI0517423A (pt) | composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto | |
| WO2006034833A1 (en) | Cyclic diarly ureas suitable as tyrosine kinase inhibitors | |
| BR0016911A (pt) | Derivados de benzazole, uso de derivados de benzazole, método para inibir a expressão e/ou atividade de jnk, método para tratamento de estados mórbidos mediado por jnk, composição farmacêutica contendo um derivado de benzazole e processo para a preparação de um derivado de benzazole | |
| RU94039542A (ru) | Производные пиперазина как антагонисты 5-нт-рецепторов, способ получения, фармацевтическая композиция | |
| BR0010716A (pt) | Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas | |
| BR9808254A (pt) | Compostos, uso e processo para a preparação dos mesmos, composição farmacêutica, e, processo para tratamento da depressão, ansiedade, doença de parkinson, obesidade, desordens cognitivas, doenças repentinas, desordens neurológicas e de neuroproteção para proteger contra condições tais como derrame cerebral em seres humanos. | |
| BRPI0410477A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto | |
| ES2131207T3 (es) | Derivados de amidas del acido valproico y 2-valproenoico y su uso como anticonvulsivos. | |
| BR0108694A (pt) | Derivados de ácido malÈnico, processo para preparação dos mesmos, uso dos mesmos como inibidor de atividade do fator xa e composições farmacêuticas que contêm os mesmos | |
| ATE181329T1 (de) | Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung | |
| AR026974A1 (es) | N-[5-[[[5-alquil-2-oxazolil]metil]tio]-2-tiazolil]-carboxamidas, utiles como inhibidores de cinasas dependientes de ciclina, y las composicionesfarmaceuticas que los contienen | |
| RU94036761A (ru) | Производные галантамина и фармацевтическая композиция | |
| DE69030616D1 (de) | Pharmazeutische Zusammensetzungen zur Hemmung der Maillardreaktion | |
| BRPI0315958B8 (pt) | composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto | |
| ES2063998T3 (es) | Uso de esteres de acidos n-alquil 1,4-dihidropiridin-dicarboxilicos como medicamentos, nuevos compuestos y procedimiento para su preparacion. | |
| ATE202551T1 (de) | Lignane, verfahren zu ihrer herstellung, ihre pharmazeutische compositionen und anwendungen | |
| MXPA04000779A (es) | 7-aza[2.2.1]bicicloheptanos sustituidos con arilo para el tratamiento de enfermedades. | |
| BR0211030A (pt) | Derivado de pirrolidina oxadiazole, uso de um derivado de pirrolidina oxadiazole, composição farmacêutica contendo pelo menos um derivado de pirrolidina oxadiazole, método para preparação de um composto de pirrolidina oxadiazole | |
| BR0010225A (pt) | Composto de amida, processo para prepará-lo, composição farmacêutica compreendendo dito composto, método de tratamento e uso | |
| ATE244221T1 (de) | Pyrrolderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
| BR9809088A (pt) | Compostos de 6,7-di-substituìdos-4-aminopirido [2,3-d] pirimidina | |
| BR9601989A (pt) | Indenoilguanidinas processo para sua preparação seus usos e medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |